MedtechInsight.com

Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home

Online Report Subscribers, Click Here

Pricing and Ordering Information

U.S. Erectile Dysfunction Therapies Market
Report #A461 - October 2011
119 Pages – 33 Exhibits – 8 Company Profiles

Erectile dysfunction (ED) is estimated to affect more than 150 million men worldwide and the number of men with ED is expected to double by the year 2030. Although most cases are not reported, it is estimated that more than 30 million men affected in the United States (U.S).

While ED is more common in men older than age 65, most men older than age 40 experience occasional difficulty; it is estimated that more than 50% of men older than age 40 report periodic episodes of ED. Despite the high number of cases, impotence is greatly undertreated, with only an estimated 15% of men seeking help from a physician due to the fact that they view the condition as personal or embarrassing.

Since the launch of Pfizer’s oral drug Viagra (sildenafil) in 1998, there has been a considerable increase in public awareness of ED due to extensive marketing by leading drug manufacturers. As a result, the worldwide market for oral ED drugs has reached more than $4.2 billion.

The U.S. market for ED therapies (defined in this report as including prescription ED drugs and penile implants) is expected to continue stable, moderate growth over the next 5 years. Valued at more than $1.9 billion in 2010, the market is expected to increase at a healthy compound annual rate of 5.1%, with sales reaching more than $2.5 billion in 2015. The U.S. ED therapies market is expected to benefit not only from continued strong demand but from highly positive demographic trends, including a large, growing ED population, strong advertising/marketing, emerging next-generation ED therapies, launch of several lower cost generic drugs, and the continued adoption of improved penile implant systems.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging drugs, technology and opportunities. Covered topics in this report include erectile dysfunction drugs (existing and emerging oral and topical ED therapies), injectable and intraurethral agents, vacuum constriction devices, penile implants, and alternative treatments.

Ordering Information

Title	Report#	Publication Date	List Price
U.S. Erectile Dysfunction Therapies Market	A461	October 2011	$3,750
Order Online: Single User only (Please call for corporate subscription pricing)			PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i. Causes and Prevention

ii. Diagnosis and Treatment

a. Oral Drug Therapy

b. Injectable and Intraurethral Drug Therapy

c. Vacuum Pump Therapy

d. Surgery/Penile Prosthesis Implantation

iii. Erectile Dysfunction Therapies Market

a. Drug Therapy

b. Penile Implants

iv. Methodology

Exhibit ES-1: Erectile Dysfunction Therapies, Combined Market Forecast, 2010-2015

1. CLINICAL OVERVIEW OF ERECTILE DYSFUNCTION

1.1 Causes and Prevention

1.2 Diagnosis and Treatment

1.2.1 Oral Drug Therapy

1.2.2 Injectable and Intraurethral Drug Therapy

1.2.3 Vacuum Pump Therapy

1.2.4 Surgery/Penile Prosthesis Implantation

1.3 Emerging Treatments

2. ERECTILE DYSFUNCTION THERAPIES MARKET

2.1 Drug Therapy

2.1.1 Oral Agents

2.1.1.1 Eli Lilly

2.1.1.2 Bayer HealthCare/Bayer

2.1.1.3 Pfizer

2.1.2 Injectable and Intraurethral Agents

2.1.2.1 Pfizer

2.1.2.2 Meda Pharmaceticals/Meda

2.1.3 Emerging Drugs

2.1.3.1 Oral Agents

2.1.3.1.1 Dong-A PharmTech/Dong-A Pharmaceutical

2.1.3.1.2 Palatin Technologies

2.1.3.1.3 Sanofi-aventis

2.1.3.1.4 SK Chemicals/SK Group

2.1.3.1.5 Vivus

2.1.3.1.6 Discontinued Clinical Development Programs

2.1.3.1.6.1 NitroMed

2.1.3.1.6.2 Novartis

2.1.3.1.6.3 Pfizer

2.1.3.2 Topical Agents

2.1.3.2.1 Futura Medical

2.1.3.2.2 Apricus Biosciences

2.1.4 Alternative Treatments

2.1.4.1 Pomegranate Extract

2.1.4.2 Testosterone Replacement Therapy

2.1.4.3 Yohimbine

2.1.4.4 Over-the-Counter Herbal Treatments

2.2 Penile Implants

2.2.1 Inflatable Implants

2.2.1.1 American Medical Systems/Endo Pharmaceuticals

2.2.1.2 Coloplast

2.2.2 Noninflatable Implants

2.2.2.1 American Medical Systems/
Endo Pharmaceuticals

2.2.2.2 Coloplast

2.3 Vacuum Constriction Devices

2.3.1 Augusta Medical Systems

2.3.2 Timm Medical Technologies/Actient Pharmaceuticals

2.3.3 Post-T-Vac Medical

2.4 Market Analysis

2.4.1 Drug Therapy Market

2.4.1.1 Patient Volumes

2.4.1.2 Market Forecast

2.4.1.3 Competitive Analysis

2.4.2 Penile Implants Market

2.4.2.1 Procedure Volumes

2.4.2.2 Market Forecast

2.4.2.3 Competitive Analysis

Exhibit 2-1: Comparative Advantages and Disadvantages of Cialis, Levitra, STAXYN, and Viagra

Exhibit 2-2: Erectile Function Improvement Using Low-Dose Once-Daily Cialis

Exhibit 2-3: Erectile Function Improvement Using Low-Dose Once-Daily Cialisin Patients with Diabetes

Exhibit 2-4: Erectile Function Improvement Using Low-Dose Once-Daily Cialis in Patients with Controlled Hypertension or Cardiovascular Disease

Exhibit 2-5: Erection Confidence Improvement Using Low-Dose Once-Daily Cialis

Exhibit 2-6: Common Adverse Events Associated with the Use of Low-Dose Once-Daily Cialis

Exhibit 2-7: Erectile Function Improvement Using High-Dose Cialis

Exhibit 2-8: Erectile Function Improvement Using High-Dose Cialis in Patients with Diabetes

Exhibit 2-9: Erectile Function Improvement Using High-Dose Cialis in Patients with Controlled Hypertension or Cardiovascular Disease

Exhibit 2-10: Erection Confidence Improvement Using High-Dose Cialis

Exhibit 2-11: Common Adverse Events Associated with the Use of High-Dose Cialis

Exhibit 2-12: STAXYN Orally Disintegrating Tablets

Exhibit 2-13: Common Adverse Events Associated with the Use of STAXYN

Exhibit 2-14: Erectile Function Improvement Using Viagra, Pivotal Efficacy Results

Exhibit 2-15: Steps Involved in the Use of the MUSE Transurethral System

Exhibit 2-16: 2011, Selected Emerging Erectile Dysfunction Products

Exhibit 2-17: Benefits and Risks of Penile Implants

Exhibit 2-18: Advantages and Disadvantages of the AMS 700 Inflatable Penile Implant

Exhibit 2-19: The AMS 700 LGX Inflatable Penile Implant

Exhibit 2-20: Advantages and Disadvantages of the AMS Ambicor Inflatable Penile Implant

Exhibit 2-21: The Titan and Titan OTR Inflatable Penile Prostheses

Exhibit 2-22: The Genesis Flexible Rod Implant

Exhibit 2-23: The SOMAerectStf Vacuum Constriction Device

Exhibit 2-24: The Vitality OTC Vacuum Constriction Device

Exhibit 2-25: The Osbon ErecAid Vacuum Therapy System

Exhibit 2-26: The BOSS 2000-3 and MVP 700 Vacuum Constriction Devices

Exhibit 2-27: Erectile Dysfunction Drug Therapy, Patient Volumes Forecast, 2010-2015

Exhibit 2-28: Erectile Dysfunction Drug Therapy, Market Forecast, 2010-2015

Exhibit 2-29: 2010, Erectile Dysfunction Drug Therapy Market, Share by Supplier

Exhibit 2-30: Penile Prosthesis Implantation, Procedure Volumes Forecast, 2010-2015

Exhibit 2-31: Penile Implants, Market Forecast, 2010-2015

Exhibit 2-32: 2010, Penile Implants Market, Share by Supplier

3. COMPANY PROFILES

3.1 American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc.

3.2 Apricus Biosciences, Inc.

3.3 Bayer AG

3.4 Futura Medical PLC

3.5 Eli Lilly and Company

3.6 Pfizer, Inc.

3.7 Reckitt Benckiser PLC

3.8 Vivus, Inc.

APPENDIX: COMPANY LISTING

To order reports or obtain information about special pre-publication offers from within the U.S., contact reports@elsevier.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.